PlasmonicTron provides the critical biological infrastructure—industrial-scale Organoids—to power the next decade of biotech innovation and Regenerative Medicine. We solve the industry's primary bottleneck: achieving high-consistency and reliability in organoid bioprocessing. 

By integrating ML-driven process control and automated cultivation, we transform manual workflows into standardized, regulatory-grade manufacturing. From NAMs-aligned drug screening to advanced scaffolds for regenerative therapies, PlasmonicTron is the industrialized total solution for biopharma and clinical partners seeking to scale biological models and accelerate the future of precision medicine.

1. Seeking U.S. partners to integrate our automated organoid manufacturing infrastructure, eliminating manual variability. We specialize in standardized cultivation for oral, neuronal, and retinal applications. We aim to collaborate with Biopharma/CROs to deploy these industrialized models for NAMs.

2. Closing $2.5M Seed round in May 2026, backed by Taiwanese industrial CVCs. Seeking U.S. investors with biotech and drug screening portfolios. We plan to initiate an extended Seed/Series A by Dec 2027 to scale our automated manufacturing capacity and accelerate U.S. market growth.

3. Targeting partners:

   • With existing organoid model, but struggling for production and application process. 

   • Working toward NIH regulatory alignment

   • Drug screening company searching for animal equialent model

   • AI drug prediction compnany that is seeking for validation of model